{"categories":["ANCA\u95a2\u9023\u8840\u7ba1\u708e","\u8840\u7ba1\u708e","\u6cbb\u7642\u85ac"],"html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Fctd-gim.hatenablog.com%2Fentry%2F2021%2F09%2F28%2F210819\" title=\"\u91cd\u75c7ANCA\u95a2\u9023\u8840\u7ba1\u708e\u306b\u5bfe\u3059\u308bRitixmab\u30fbCyclophosphamide\u30fb\u8840\u6f3f\u4ea4\u63db\u306e\u4f75\u7528\u7642\u6cd5 - \u81a0\u539f\u75c5\u30fb\u30ea\u30a6\u30de\u30c1\u4e00\u4eba\u6284\u8aad\u4f1a\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","url":"https://ctd-gim.hatenablog.com/entry/2021/09/28/210819","blog_title":"\u81a0\u539f\u75c5\u30fb\u30ea\u30a6\u30de\u30c1\u4e00\u4eba\u6284\u8aad\u4f1a","author_name":"CTD_GIM","published":"2021-09-28 21:08:19","author_url":"https://blog.hatena.ne.jp/CTD_GIM/","description":"Gulati K, Edwards H, Prendecki M, et al. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis [published online ahead of print, 2021 Sep 21]. Kidney Int. 2021;S0085-2538(21)00859-0. doi:10.1016/j.kint\u2026","image_url":null,"version":"1.0","title":"\u91cd\u75c7ANCA\u95a2\u9023\u8840\u7ba1\u708e\u306b\u5bfe\u3059\u308bRitixmab\u30fbCyclophosphamide\u30fb\u8840\u6f3f\u4ea4\u63db\u306e\u4f75\u7528\u7642\u6cd5","provider_url":"https://hatena.blog","provider_name":"Hatena Blog","blog_url":"https://ctd-gim.hatenablog.com/","width":"100%","height":"190","type":"rich"}